TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26220763
Drug: Probiotics (Bifidobacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Bifidobacterium supplements)
Study: 24983746
Drug: Semagacestat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semagacestat (100 mg and 140 mg)
Study: 19892338
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy (group 1)
Study: 9744372
Drug: Latanoprost treatment
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost treatment
Study: 16822992
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (ECF regimen: epirubicin 50 mg/m², cisplatin 60 mg/m², fluorouracil 200 mg/m²/day for 21 days) and surgery
Study: 16822992
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (ECF regimen)
Study: 8956299
Drug: Nifedipine infusion
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine infusion from isolation of aorta until end of surgery (group A)
Study: 8956299
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine infusion over the same surgical course (group B)
Study: 1286501
Drug: Flumazenil (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (maximum dose of 1 mg, administered intravenously at 0.2 mg at 1-minute intervals)
Study: 1286501
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 ml administered at 1-minute intervals)
Study: 3927551
Drug: Leuprolide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (1 mg per day, subcutaneous injection)
Study: 3927551
Drug: Diethylstilbestrol (DES)
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES) (3 mg per day, oral)
Study: 10453373
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (maximum dose 22 mg/day)
Study: 7598064
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (1.47 g protein.kg body cell mass‐1.d‐1)
Study: 7598064
Drug: Adequate-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate-protein diet (2.94 g protein.kg body cell mass‐1.d‐1)
Study: 31823206
Drug: Topical Low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Low Dose Preservative-Free Hydrocortisone
Study: 30640654
Drug: Intravenously applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenously applied morphine
Study: 19683639
Drug: Percutaneous closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous closure of the left atrial appendage (LAA) and subsequent discontinuation of warfarin (n=463)
Study: 19683639
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment with a target international normalised ratio between 2.0 and 3.0 (n=244)
Study: 16320926
Drug: L-arginine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (7.5 g in 500 ml of cardioplegic solution)
Study: 7714648
Drug: Pneumatic sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumatic sequential leg compression devices (PSLCDs)
Study: 2522110
Drug: Sulpiride treatment
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride treatment
Study: 31982695
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of neutrophil chemotaxis activity with mHLA-DR, CD-11b expression, presepsin, and SOFA score
Study: 25425655
Drug: Budesonide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (mean dose 4.5 mg/day; Budenofalk 3 mg capsules, two or one capsule on alternate days)
Study: 8776122
Drug: Intradermal pins
Normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal pins
Study: 2060255
Drug: 2% MK-927
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% MK-927 (1.2 mg) q.i.d.
Study: 2060255
Drug: 1.8% sezolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8% sezolamide (1.1 mg) q.i.d.
Study: 31124272
Drug: rFVIIa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (100 ± 20 μg/kg dose)
Study: 27139057
Drug: Chemotherapy (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (1000 mg/m2 weekly of gemcitabine)
Study: 27139057
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus erlotinib (100 mg/d)
Study: 26017589
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (45 mg) applied to mastectomy skin at the time of surgical dressing
Study: 22236639
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound therapy (Control)
Study: 20068494
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg x kg(-1) body mass)
Study: 27548794
Drug: Caffeine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (various doses)
Study: 11838628
Drug: Sertraline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline treatment (50 to 200 mg/day) during the acute phase
Study: 11838628
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with sertraline
Study: 11838628
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of sertraline (double-blind)
Study: 7677455
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) + Glutamine (GLN) + Diet (DIET)
Study: 7677455
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy with GH + GLN + DIET
Study: 2119392
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg leuprolide acetate (GnRH agonist)
Study: 27484017
Drug: Staloral® (12000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staloral® (12000 BAU/ml)
Study: 27484017
Drug: Soluprick® (10300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluprick® (10300 BAU/ml)
Study: 27484017
Drug: Reference extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference extract (10000 BAU/ml)
Study: 18495456
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment with varying total choline (344-486 mg/day), betaine (122-349 mg/day) and/or folate (400-800 microg dietary folate equivalents/day) for 12 weeks
Study: 11883349
Drug: 10‐mg PGE2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg PGE2 vaginal insert
Study: 11883349
Drug: 3‐mg PGE2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐mg PGE2 tablets (administered twice at six‐hour intervals)
Study: 11883349
Drug: 3‐mg PGE2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐mg PGE2 tablets
Study: 2115444
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (10 mg(24 h)‐1)
Study: 2115444
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (mean dose: 40 +/‐ 9 micrograms min‐1)
Study: 7355391
Drug: Cimetadine (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetadine (three preoperative doses)
Study: 7355391
Drug: Glycopyrrolate (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.005 mg/kg)
Study: 31711605
Drug: i.v. dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. dexamethasone 2 mg
Study: 31711605
Drug: i.v. dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. dexamethasone 4 mg
Study: 26921136
Drug: Vaginal progesterone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone, 200 mg daily from 22-24 to 34 weeks of gestation
Study: 24052092
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (10-week intervention)
Study: 20209088
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (≥800 IU orally daily)
Study: 18520275
Drug: Modified forearm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified forearm minidose intravenous regional anesthesia (IVRA)
Study: 18520275
Drug: Conventional minidose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional minidose intravenous regional anesthesia (IVRA)
Study: 15925082
Drug: Tadalafil 20mg
Normalized name: TADALAFIL 20MG TAB
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 20mg on demand (maximum one dose per day before sexual activity)
Study: 7579093
Drug: Plasma clearance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma clearance of iohexol (single iv dose)
Study: 19779705
Drug: Oral cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporin A
Study: 26493396
Drug: Continuous caudal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous caudal epidural bupivacaine 0.125 % with fentanyl, IV fentanyl, and paracetamol
Study: 26493396
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl and paracetamol
Study: 20061693
Drug: Intraluminal vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraluminal vancomycin (500 mg infusion via both lumens of the Permcath and antibiotic lock of 1.5 mL every 48 hours) and intravenous ceftriaxone (1 g every 12 hours for 7 days) followed by oral antibiotics for three weeks
Study: 20061693
Drug: Intravenous vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vancomycin (500 mg) and daily intravenous amikacin (100-150 mg)
Study: 18834241
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy before 21 weeks' gestation
Study: 2699207
Drug: d-fenfluramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (15 mg p.o. twice daily)
Study: 25825855
Drug: 4‐week outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐week outpatient treatment by the same multidisciplinary team
Study: 21764118
Drug: Sertraline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (150 mg per day)
Study: 21764118
Drug: Mirtazapine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (45 mg)
Study: 19517423
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg venlafaxine tablets
Study: 17082465
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and ongoing medical care (Control)
Study: 7991719
Drug: standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard dose of neuroleptic
Study: 2604291
Drug: Combined formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined formulation of isoniazid (125 mg), rifampin (100 mg), and pyrazinamide (375 mg)
Study: 2604291
Drug: Separate formulations
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate formulations of isoniazid, rifampin, and pyrazinamide
Study: 2604291
Drug: Combined formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined formulation
Study: 26106962
Drug: Separate formulations
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate formulations
Study: 23271193
Drug: Drug Effects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Effects Questionnaire (DEQ) for amphetamine
Study: 23271193
Drug: Drug Effects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Effects Questionnaire (DEQ) for nicotine
Study: 23271193
Drug: Drug Effects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Effects Questionnaire (DEQ) for alcohol
Study: 16835255
Drug: Intra-articular magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular magnesium sulphate (MgSO4) 10 ml (50 mg/ml)
Study: 16835255
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 ml (Control Group)
Study: 11808835
Drug: Smoking reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking reduction (4-8 cigarettes daily)
Study: 8775880
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy with aspirin
Study: 8775880
Drug: Novel antiplatelet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel antiplatelet and antithrombotic agents
Study: 2342740
Drug: Preterm birth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preterm birth prevention program consisting of risk scoring, intensive weekly observation including cervical examinations, and detailed education about preterm labor signs and symptoms.
Study: 2342740
Drug: Preterm birth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preterm birth prevention program (treatment group).
Study: 7449720
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Quinupramine
Study: 7449720
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Quinupramine
Study: 6832466
Drug: Indobufen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (200 mg single oral dose)
Study: 30935809
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT), 0.340 mJ/mm2, 2000 shots
Study: 25377370
Drug: Trazodone (hypnotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (hypnotic doses)
Study: 25377370
Drug: Zopiclone (hypnotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (hypnotic agent)
Study: 18946743
Drug: Cholestyramine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 2 g BID, methimazole, and propranolol
Study: 18946743
Drug: Cholestyramine 1
Normalized name: CHOLESTYRAMINE 1GM TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 1 g BID, methimazole, and propranolol
Study: 11838627
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (100 mg/day increasing to 400 mg/day over 4 weeks)
Study: 25920468
Drug: Church-based diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Church-based diabetes self-management program (eight weekly group classes led by trained lay leaders)
Study: 23630211
Drug: G‐CSF throughout
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF throughout all chemotherapy cycles
Study: 23630211
Drug: G‐CSF during
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF during the first two cycles only
Study: 17695603
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide (HP) concentrations ranging from 15% to 35% with treatment contact times of 15 to 60 minutes.
Study: 15096085
Drug: Lamotrigine (50‐400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (50‐400 mg/day fixed dose or 100‐400 mg/day flexible dose)
Study: 15096085
Drug: Lithium (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (serum level of 0.8‐1.1 mEq/L)
Study: 12017403
Drug: Sumatriptan 50
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 50 mg alone
Study: 12017403
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Sumatriptan 50 mg + Clarithromycin 500 mg)
Study: 12017403
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Sumatriptan alone and Combination treatment)
Study: 2373130
Drug: Energy deficient
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy deficient diet (daily energy intake 4.3 MJ; daily protein intake 0.94 g/kg)
Study: 2373130
Drug: Protein deficient
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein deficient diet (daily energy intake 11.4 MJ; daily protein intake 0.31 g/kg)
Study: 2373130
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (daily energy intake 12.0 MJ; daily protein intake 1.52 g/kg)
Study: 7032558
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine tablets (MST-1; 2 x 10 mg)
Study: 7032558
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine sulphate in solution (20 mg)
Study: 7032558
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine tablets (MST-1)
Study: 25196040
Drug: Caffeine-glucose combination
Normalized name: caffeine / glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-glucose combination (60g glucose + 40mg caffeine)
Study: 22120913
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy (deferasirox)
Study: 21194441
Drug: Intra-articular interleukin-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular interleukin-1 receptor antagonist (IL-1Ra) therapy
Study: 14561016
Drug: Cardioselective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioselective beta-blockers
Study: 2564723
Drug: Terazosin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin monotherapy
Study: 2564723
Drug: Methyclothiazide (MCTZ)
Normalized name: Methyclothiazide
DrugBank: Methyclothiazide (DB00232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyclothiazide (MCTZ) monotherapy
Study: 2564723
Drug: Terazosin/MCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin/MCTZ combination therapy
Study: 2564723
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy vs. monotherapy
Study: 28058491
Drug: Hypomethylating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypomethylating therapy with decitabine
Study: 26248593
Drug: Simeprevir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (150 mg for 7 days)
Study: 26248593
Drug: Simeprevir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (200 mg single dose)
Study: 24051622
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (SEQ) with chemical nail avulsion, RV4104A ointment (40% urea), ciclopirox cream for 8 weeks, and ciclopirox nail lacquer for 25 weeks
Study: 24051622
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (SEQ)
Study: 20444308
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg/kg) followed by lactate (10 mg/kg)
Study: 17036484
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic drug (control group)
Study: 17036484
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral hypoglycemic drug)
Study: 14743961
Drug: Pravastatin 80
Normalized name: pravastatin 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 80 mg/day for 8 weeks
Study: 10719694
Drug: Conventional Treatment
Normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Treatment Position (CTP)
Study: 8732493
Drug: Hyperinsulinaemic, euglycaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinaemic, euglycaemic clamp (1 mu kg‐1 min‐1, 5 mmol L‐1)
Study: 7904767
Drug: Sodium chromoglycate
Normalized name: cromoglycate
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chromoglycate 10 mg q.i.d. for 4 weeks (control)
Study: 27440671
Drug: rhBMP-2/ACS (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBMP-2/ACS (1.5 mg/ml; total dose 4.2 mg)
Study: 10687882
Drug: E2 Matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 Matrix 0.10 mg
Study: 10687882
Drug: E2 Matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 Matrix 0.05 mg
Study: 8440761
Drug: Ethanol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (25 mL in 150 mL of grapefruit juice)
Study: 3532535
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal therapy with diethylstilbestrol
Study: 3532535
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal therapy with tamoxifen
Study: 25380842
Drug: Endoscopic sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sequential treatment (Group A: local chemotherapeutic drug injection with ordinary metal stent implantation)
Study: 25380842
Drug: Endoscopic sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sequential treatment (Group B: local chemotherapeutic drug injection with iodine‐125 particle implantation)
Study: 25380842
Drug: Endoscopic sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sequential treatment (Group C: radiofrequency therapy with ordinary metal stent)
Study: 25380842
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (Group D: local chemotherapeutic drug injection)